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Abstract
This work proposes a pipeline to predict treatment response to intra-arterial ther-
apy of patients with Hepatocellular Carcinoma (HCC) for improved therapeutic
decision-making. Our graph neural network model seamlessly combines heteroge-
neous inputs of baseline MR scans, pre-treatment clinical information, and planned
treatment characteristics and has been validated on patients with HCC treated by
transarterial chemoembolization (TACE). It achieves Accuracy of 0.713±0.075, F1
of 0.702± 0.082 and AUC of 0.710± 0.108. In addition, the pipeline incorporates
uncertainty estimation to select hard cases and most align with the misclassified
cases. The proposed pipeline arrives at more informed intra-arterial therapeutic
decisions for patients with HCC via improving model accuracy and incorporating
uncertainty estimation.
1 Introduction
Hepatocellular carcinoma (HCC), primary liver cancer, has the fastest rising incidence rates world-
wide, especially in the western countries [1]. Transarterial chemoembolization (TACE) has been a
well established primary therapy for patients with unresectable HCC [2]. The assessment of patients
after TACE treatment has been advanced by the quantitative European Association for the Study of
the Liver (qEASL) response criterion, which quantitatively measures the degree of change in 3D
enhancing tumor volume instead of 2D measurement or visual estimation. However, it still remains a
clinical challenge to predict which patients will respond to TACE before treatment [3].
Why does early prediction before treatment matter? Data-driven methods for medical imaging have
been emphasized more on the analytical models such as segmentation and classification for diagnostic
purposes compared to predictive models [4]. However, the advancement in predictive models to
predict future medical observations, such as disease progression [5], survival and prognosis [6], and
treatment response [3], with high precision could impact the development of treatment procedures
and could modify treatment strategy. Here, we focus on treatment response prediction of the TACE
procedure. Predicting and identifying non-responders to TACE prior to initiation of therapy carries
significant potential survival benefits for non-responders, should such patients be allowed to enter
alternative, e.g. systemic, therapies.
Previous work on treatment response relies heavily on clinical features and handcrafted radiomics
features [3][7]. Recently, more and more convolutional neural networks that take images as inputs
have been utilized for treatment response prediction [8][9][10]. However, integration of readily-
available non-imaging data, such as clinical information and treatment characteristics, would likely
improve prediction accuracy. This paper leverages recent advances in graph neural networks, which
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Figure 1: Two examples of qEASL analysis, left is
from responder, right is from non-responder. For each
example, left is baseline scan, right is follow-up scan.
We can see the qEASL value drops from 40.17 to 2.94
cm3 for responder, while the qEASL value drops from
246.12 to 424.86 cm3 for non-responder. Similar esti-
mation is performed three times for each patient and
averaged to generate the final ground truth label.
Figure 2: Generating node feature vectors
from 3D volumes using autoencoder.
has shown the power of handling heterogeneous inputs. In medical imaging, it has been widely used
for brain data analysis, e.g., to handle imaging and non-imaging data [11] and to identify biomarkers
from complicated relationships [12].
This paper presents the first work to explore graph neural networks for prediction of treatment
response. Some level of uncertainty exists not only in the model and data, but also in the ground truth
labels (as illustrated in Sec. 2). The pipeline incorporates uncertainty estimation to select difficult
cases that are often misclassified.
2 Method
Problem formulation Pre-treatment baseline data from HCC patients are collected. We aim to
predict TACE treatment response (one month follow-up) from baseline data. Since treatment response
can be assessed by changes in qEASL value [3] and over a 65% reduction in qEASL between baseline
and follow-up imaging indicates responders, the prediction problem can be conceptualized as a
classification problem.
Data The dataset consists of 83 patients with HCC treated by TACE. Both baseline and one month
follow-up multi-phasic MR scans are collected. Non-imaging data includes pre-treatment clinical
information (laboratory values, clinical history, etc) and planned treatment characteristics. As
mentioned above, 65% drop in qEASL indicates responders. To generate ground truth labels, qEASL
analysis was performed on both baseline MR and one month follow-up MR scans and changes were
computed accordingly. 20-second arterial phase images were selected for qEASL analysis, as shown
in Fig. 1. qEASL values are essentially the enhancing tumor volume expressed as a percentage of the
total tumor volume. To estimate qEASL, each measurement includes three parenchymal regions of
interest (ROIs) to generate an average, serving as the estimated parenchymal intensity.
Pipeline The proposed prediction pipeline consists of three steps, as shown in Fig. 3. First, build the
graph using both imaging and non-imaging data, where each patient serves as a node. Second, train
the graph convolutional neural network (GCN) with softmax for semi-supervised classification on the
above graph to get prediction results. Third, use Monte Carlo (MC) dropout as Bayesian estimation
for uncertainty estimation to identify hard cases for more informed decision-making.
To build the graph, node feature vectors encoding imaging information are generated by a 3D
autoencoder (AE) model as shown in Fig. 2. The AE model is fed concatenated liver and tumor
3D volumes and trained on the self-reconstruction task. The AE latent vectors of length of 128 are
extracted as node feature vectors. Graph edges incorporate the non-imaging data. According to
the prior knowledge from physicians, two binary features from both clinical information (Cirrhosis
presence) and treatment characteristics (Sorafenib) are selected. An edge is drawn for each binary
feature whose status is shared between two patients to form the adjacency matrix. Correlations
between each pair of nodes are computed to be applied as weights on the above adjacency matrix.
The graph convolutional neural network (GCN) [13] was trained on the graph built above. The
structure of the GCN consists of convolutional layers, Rectified Linear Units (ReLU), and a softmax
activation function at the end. To avoid over-fitting and realize uncertainty estimation, a dropout rate
of 0.15% was applied during both training and testing. To train the prediction model, the cross-entropy
loss function was calculated only over labelled training nodes during training stage, and then used
2
Figure 3: Pipeline for predicting treatment response using GCN and uncertainty estimation.
Table 1: Comparison of prediction performance
Method Accuracy (std) F1 (std) AUC (std)
RF 0.58± 0.06 0.57± 0.08 0.60± 0.08
GCN 0.71± 0.07 0.70± 0.08 0.71± 0.10
Ablation 1 w/o Cirrhosis 0.64± 0.05 0.62± 0.06 0.66± 0.09
Ablation 2 w/o Sorafenib 0.65± 0.05 0.63± 0.07 0.59± 0.07
Ablation 3 w/o non-imaging 0.59± 0.03 0.57± 0.06 0.63± 0.11
for updating the parameters in the GCN. During testing stage, unlabelled testing nodes are assigned
labels according to the output of the softmax.
To generate the final prediction and corresponding uncertainty estimation, MC dropout [14] was
utilized. For each sample, predictions were performed 100 times using the GCN model with dropout.
The final prediction was decided by majority voting. Confidence of the prediction was estimated
quantitatively by the ratio of predictions that agreed with the final prediction. The confidence level
for each prediction can be used to select the most uncertain cases, as they are likely to be the difficult
cases that are more likely to be misclassified.
3 Results and Analysis
Classification results 10-fold cross-validation was applied for evaluation. Please refer to Table 1 for
details. GCN is the graph convolutional neural network model in the above proposed pipeline. RF is
a random forest model with the same imaging and binary non-imaging features as inputs where PCA
was used for dimensional reduction. Ablation 1-3 w/o Cirrhosis/Sorafenib/non-imaging refers to
building the graph without Cirrhosis/Sorafenib/both non-imaging features. GCN shows a significant
improvement in prediction performance compared to the random forest model. The ablation studies
show that the proper construction of the graph with prior knowledge is essential for the success of
GCN. The drop in performance for each ablation study corresponds to the importance of the dropped
non-imaging feature.
Uncertainty estimation Uncertainty estimation [14] was achieved by MC dropout during the test
stage. By ruling out test cases with the lowest confidence, we can see the classification performance
generally improves, which shows that the majority of low confidence cases align with misclassified
cases. Specifically, when ruling out cases with confidence lower than 85%, 90%, 95%, computed on
remaining cases, F1 improves by 3.76%, 3.6%, 5.76%, AUC improves by 2.11%, 3.56%, 8.61%, and
Accuracy improves by 5.45%, 6.58%, 10.61%.
4 Conclusion
In summary, the proposed pipeline arrives at more informed intra-arterial therapeutic decisions
for HCC patients via improving model accuracy and incorporating uncertainty estimation. GCN
incorporates prior knowledge into the graph construction and combines both imaging and non-
imaging features. Uncertainty estimation serves as an essential role towards more informed clinical
decision-making. Yet, much remains to be improved. For future research, more flexible graph
construction such as constructing multiple graphs instead of one graph could help incorporate more
prior information. Other uncertainty estimation methods should also be investigated.
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